Literature DB >> 1587820

Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate.

J E Turnbull1, D G Fernig, Y Ke, M C Wilkinson, J T Gallagher.   

Abstract

The structural properties of fibroblast heparan sulfate (HS) that are necessary for it to bind strongly to basic fibroblast growth factor (bFGF) have been investigated using bFGF affinity chromatography. Specific enzymic and chemical scission of HS, together with chemical N-desulfation, revealed that N-sulfate groups and iduronate-2-sulfates (IdoA(2-OSO3)) were essential for the interaction. bFGF-affinity chromatography of sulfated oligosaccharides released from HS by treatment with heparitinase led to the identification of an oligosaccharide component (oligo-H), seven disaccharides in length, with a similar affinity for bFGF as the parent molecule. Heparinase treatment of this fraction abolished the high affinity binding to bFGF. Analysis of oligo-H indicated that 74% of the disaccharide units had the structure IdoA(2-OSO3)alpha 1,4GlcNSO3; the remainder comprised N-acetylated and N-sulfated units, the majority of which were devoid of O-sulfate groups. Oligo-H was fully degraded to disaccharides by treatment with nitrous acid. These results indicate that the sequence of oligo-H is as shown below. delta GlcA beta 1,4GlcNSO3 alpha 1,4[IdoA(2-OSO3)alpha 1,4GlcNSO3]5 alpha 1, 4IdoA alpha 1,4GlcNAc Sulfated oligosaccharides of similar size but with a lower affinity for bFGF had a reduced concentration of IdoA(2-OSO3) but significant quantities of GlcNSO3(6-OSO3) and GlcNAc(6-OSO3). The data indicate a primary role for contiguous sequences of IdoA(2-OSO3)alpha 1,4GlcNSO3 in mediating the high affinity binding between fibroblast HS and bFGF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1587820

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  117 in total

Review 1.  Angiogenesis in inflammatory joint disease: a target for therapeutic intervention.

Authors:  P E Brenchley
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  A rapid quantitative assay for the detection of mammalian heparanase activity.

Authors:  C Freeman; C R Parish
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

3.  Screening for anticoagulant heparan sulfate octasaccharides and fine structure characterization using tandem mass spectrometry.

Authors:  Hicham Naimy; Nancy Leymarie; Joseph Zaia
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

4.  Peptide- and protein-mediated assembly of heparinized hydrogels.

Authors:  Kristi L Kiick
Journal:  Soft Matter       Date:  2008-01-01       Impact factor: 3.679

5.  Heparinase inhibits neovascularization.

Authors:  R Sasisekharan; M A Moses; M A Nugent; C L Cooney; R Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

6.  Interactions of putative heparin-binding domains of basic fibroblast growth factor and its receptor, FGFR-1, with heparin using synthetic peptides.

Authors:  L Kinsella; H L Chen; J A Smith; P S Rudland; D G Fernig
Journal:  Glycoconj J       Date:  1998-04       Impact factor: 2.916

Review 7.  Heparan sulfate 2-O-sulfotransferase (Hs2st) and mouse development.

Authors:  Valerie A Wilson; John T Gallagher; Catherine L R Merry
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

8.  Expression of basic fibroblast growth factor in intact and ulcerated human gastric mucosa.

Authors:  M A Hull; J L Brough; D G Powe; G I Carter; D Jenkins; C J Hawkey
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

9.  Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry.

Authors:  B C Herold; S I Gerber; B J Belval; A M Siston; N Shulman
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

Review 10.  Heparan sulfate and heparin interactions with proteins.

Authors:  Maria C Z Meneghetti; Ashley J Hughes; Timothy R Rudd; Helena B Nader; Andrew K Powell; Edwin A Yates; Marcelo A Lima
Journal:  J R Soc Interface       Date:  2015-09-06       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.